AT
Therapeutic Areas
Xenetic Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Systemic DNase I | Pancreatic Carcinoma | Pre-clinical |
| DNase-Armored CAR T Platform | Multiple Solid Cancers | Research |
Leadership Team at Xenetic Biosciences
JF
James F. Parslow
Interim Chief Executive Officer and Chief Financial Officer
SN
Scott N. Cullison
Executive Consultant for Business Development
RP
Reid P. Bissonnette, Ph.D.
Executive Consultant for Translational Research and Development
GG
Grigory G. Borisenko, Ph.D.
Non-Executive Director
FJ
Firdaus Jal Dastoor, FCS
Non-Executive Director
DG
Dmitry Genkin, MD
Non-Executive Director
RK
Roger Kornberg, Ph.D.
Non-Executive Director
JS
Jonathan Spicer, M.D., Ph.D.
Scientific Advisory Board Member
MF
Matthew Frigault, M.D.
Scientific Advisory Board Member